Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Understanding the Influence of Concomitant Irritable Bowel Syndrome (IBS) on Gastro-Oesophageal Reflux Disease (GORD), Including GORD-related Symptoms, GORD Severity, Oesophageal Motility, and Multi-Channel Intraluminal Impedance-pH Findings.

NCT06615856 is registered in ClinicalTrials.gov with The Leeds Teaching Hospitals NHS Trust as lead sponsor.

NCT NCT06615856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Understanding the Influence of Concomitant Irritable Bowel Syndrome (IBS) on Gastro-Oesophageal Reflux Disease (GORD), Including GORD-related Symptoms, GORD Severity, Oesophageal Motility, and Multi-Channel Intraluminal Impedance-pH Findings.
Lead sponsor
The Leeds Teaching Hospitals NHS Trust
Phase
Observational
Overall status
Not yet recruiting
Start date
October 14, 2024
Completion date
May 31, 2025
Enrollment
124 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-oesophageal reflux disease, irritable bowel syndrome